上海口腔医学 ›› 2020, Vol. 29 ›› Issue (4): 418-422.doi: 10.19439/j.sjos.2020.04.017

• 论著 • 上一篇    下一篇

IL-23R基因多态性与复发性口腔溃疡易感性及临床疗效的相关性分析

孙海涛1, 冯小东2   

  1. 1.首都医科大学附属北京世纪坛医院 口腔科,北京 100038;
    2.首都医科大学附属北京同仁医院 口腔科,北京 100730
  • 收稿日期:2020-02-27 修回日期:2020-04-23 出版日期:2020-08-25 发布日期:2020-09-11
  • 通讯作者: 冯小东,E-mail:boycant@qq.com
  • 作者简介:孙海涛(1975-),男,博士,主治医师,E-mail:dr_sht@163.com

Correlation analysis on single nucleotide polymorphism of IL-23 receptor gene to susceptibility and clinical efficacy of recurrent oral ulcer

SUN Hai-tao1, FENG Xiao-dong2   

  1. 1. Department of Stomatology, Beijing Shijitan Hospital Affiliated to Capital Medical University. Beijing 100038;
    2. Department of Stomatology, Beijing Tongren Hospital Affiliated to Capital Medical University. Beijing 100730, China
  • Received:2020-02-27 Revised:2020-04-23 Online:2020-08-25 Published:2020-09-11

摘要: 目的:探讨白细胞介素 23 受体(Interleukin- 23 receptor,IL-23R)rs11465817 和 rs10489629位点基因多态性与复发性口腔溃疡(recurrent oral ulcer,ROU)易感性及临床疗效的相关性。方法:选择2016年1月—2018年12月于北京世纪坛医院口腔科就诊的150例ROU患者,同时选取同期在医院体检的健康受试者150例作为健康对照组。提取所有受试者血液DNA,采用聚合酶链反应(PCR)对IL-23R rs11465817 和 rs10489629位点基因进行扩增,对扩增产物进行酶切反应后,再做电泳,以确定基因分型。对ROU患者采用口服左旋咪唑片、维生素 C 片、维生素 B2片以及西吡氯铵漱口进行治疗。治疗前与治疗1周后采用溃疡面积和疼痛指数进行临床疗效评估。分析IL-23R rs11465817 和 rs10489629位点基因多态性与ROU易感性及临床疗效的相关性。采用SPSS 22.0软件包对数据进行统计学分析。结果:健康对照组IL-23R rs11465817和IL-23R rs10489629基因分型分布符合 Hardy-Weinberg 平衡(P>0.05),ROU组患者IL-23R rs11465817位点CC和CA基因型分布频率显著高于健康对照组(P<0.05)。Logistic回归分析显示,携带CC、CA基因型患者ROU风险较高(P<0.05)。2组受试者IL-23R rs10489629位点基因分型频率差异无统计学意义(P>0.05);Logistic回归分析显示,IL-23R rs10489629位点基因分型与ROU敏感性无关(P>0.05)。治疗后ROU患者平均溃疡面积和VAS评分显著降低(P<0.05)。治疗结束时,IL-23R rs11465817位点AA基因型ROU患者溃疡面积和VAS评分显著低于CC或CA基因型患者(P<0.05)。治疗结束时,IL-23R rs10489629位点各基因型ROU患者溃疡面积和VAS评分差异均无统计学意义(P>0.05)。结论:IL-23R rs11465817位点基因多态性与ROU易感性相关,可能影响ROU的临床疗效;而IL-23R rs10489629位点基因多态性与ROU易感性无关,并且对ROU疗效无显著影响。

关键词: IL-23R, 基因多态性, 复发性口腔溃疡, 临床疗效

Abstract: PURPOSE: To investigate the correlation of gene polymorphisms of interleukin-23 receptor (IL-23R) rs11465817 and rs10489629 loci to susceptibility and clinical efficacy of recurrent oral ulcer (ROU). METHODS: A total of 150 ROU patients, who visited Stomatological Department of our hospital from January 2016 to December 2018, were selected as ROU group. A total of 150 healthy subjects who underwent physical examination at the same time in our hospital, were selected as healthy control group. Blood DNA was extracted from all subjects and amplified by polymerase chain reaction (PCR) at sites of IL-23R rs11465817 and rs10489629 loci. The genotyping was determined by electrophoresis after enzymatic digestion of amplified products. Patients with ROU were treated with oral levamisole, vitamin C, vitamin B2 and cetylpyridnium chloride gargle. Ulcer area and pain index were used to evaluate the clinical efficacy before and in the first week after treatment. Correlation on gene polymorphisms of interleukin-23 receptor (IL-23R) rs11465817 and rs10489629 loci to susceptibility and clinical efficacy of ROU was analyzed. SPSS 22.0 software package was used for statistical analysis of the data. RESULTS: Genotyping distribution of IL-23R rs11465817 and il-23r rs10489629 loci in healthy control group met Hardy-Weinberg equilibrium (P>0.05). Distribution frequency of CC and CA genotypes of IL-23R rs11465817 loci in ROU group was significantly higher than that in healthy control group (P<0.05), and logistic regression analysis showed that ROU risk in patients with CC and CA genotypes was significantly higher (P<0.05). The genotyping frequency of IL-23R rs10489629 loci was not significantly different between both groups (P>0.05). Logistic regression analysis showed that genotyping of IL-23R rs10489629 loci was not correlated with ROU sensitivity (P>0.05). The mean ulcer area and VAS score of ROU patients was significantly reduced after treatment (P<0.05). The ulcer area and VAS score in patients with IL-23R rs11465817 loci of AA genotype was significantly lower than that in patients with IL-23R rs11465817 loci of CC or CA genotype (P<0.05). Ulcer area and VAS score in patients with IL-23R rs10489629 locus of each genotype was not significantly different (P>0.05). CONCLUSIONS: Polymorphism of IL-23R rs11465817 loci is probably related to susceptibility and clinical efficacy of ROU, while polymorphism of IL-23R rs 10489629 is not probably related to susceptibility and clinical efficacy of ROU. The results of this study need to be further validated by a clinical study with large sample size.

Key words: IL-23R, Gene polymorphism, Recurrent oral ulcer, Clinical efficacy

中图分类号: